SCHEMBL24568403

SCHEMBL24568403

Nc1nc(-c2cc(Cl)ccc2F)cc(-c2cccnc2)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
GAA P10253 3/20 0.47
GLA P06280 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
IKBKB O14920 1/20 0.46
CYP11B1 P15538 7/20 0.43
CYP11B2 P19099 7/20 0.43
EPHB4 P54760 1/20 0.43
ERN1 O75460 1/20 0.42
CYP17A1 P05093 3/20 0.41
ACLY P53396 1/20 0.41
ADORA2A P29274 1/20 0.41
BCHE P06276 1/20 0.41
CYP3A4 P08684 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24568794 0.87 CYP11B1 (0.45) KDM4ECYP11B1CYP11B2ERN1CYP17A1
SCHEMBL28994427 0.86 TGFBR1 (0.46) ACLYBCHECYP3A4RAB9ACYP1A2
SCHEMBL28115752 0.81 CYP2A6 (0.51) KDM4EALDH1A1CYP11B1CYP11B2ERN1
SCHEMBL24569028 0.78 HSP90AA1 (0.40) ALDH1A1HPGDSMN1; SMN2ADORA2AACVR1B
SCHEMBL24568836 0.77 ERN1 (0.46) CYP11B1CYP11B2ERN1CYP17A1CYP3A4
SCHEMBL29694333 0.77 ERN1 (0.46) CYP11B1CYP11B2ERN1CYP17A1CYP3A4
SCHEMBL29694366 0.76 AMY1A (0.40) ACVR1BTGFBR1ACVRL1
SCHEMBL24568805 0.76 AGPAT2 (0.41) CYP3A4ACVR1BTGFBR1ACVRL1
SCHEMBL24568807 0.76 AMY1A (0.40) ACVR1BTGFBR1ACVRL1
SCHEMBL24568840 0.74 BCHE (0.41) KDM4EGAAGLAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116948-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-04-11 US disclosed
EP-4267584-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-11-01 EP disclosed
WO-2022136221-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-30 WO disclosed
WO-2022136221-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116948-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS TGFBR1, ACVR1, TGFBR2 KDM4E 886/4885GAA 1371/4885GLA 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.